CVS Health CEO Karen Lynch Resigns Amid Struggles and Stock Decline

CVS Health CEO Karen Lynch has resigned as the company faces significant challenges and a 19 percent decline in stock value this year.

Lynch, who took over in 2021, will be replaced by David Joyner, a veteran executive who previously led CVS Caremark, the company’s pharmacy benefits management (PBM) division.

The leadership change follows a series of financial setbacks for CVS, including missed earnings targets and rising medical costs, particularly in its Medicare Advantage plans.

CVS had already lowered its earnings forecasts three times this year.

On Friday, the company warned that third quarter earnings would fall well below expectations, causing shares to drop an additional 9.9 percent, reaching $57.40​​.

CVS, one of the largest U.S. drugstore chains, has struggled to balance its expansive operations, which include its Aetna insurance arm, covering 27 million people.

Increased costs from Medicare Advantage claims have significantly impacted the company’s bottom line. Analysts had predicted third quarter earnings of $1.69 per share, but CVS now expects between $1.05 and $1.10 per share​.

These financial pressures have been exacerbated by a drop in quality ratings for its Medicare Advantage plans, along with ongoing challenges in managing Medicaid coverage in several states.

CVS also faced growing competition from online retailers and other health services, which further strained its retail business​.

The company has also faced pressure from Glenview Capital Management, a hedge fund that holds a stake in CVS.

Glenview has called for improvements in CVS’s governance and efficiency, urging changes to strengthen the company’s investment strategy and operational performance.

David Joyner, with 37 years of experience in health care and pharmacy benefits, will lead CVS through this turbulent period.

Joyner’s previous role overseeing CVS Caremark gives him deep insight into the company’s PBM business, which serves about 90 million members. Roger Farah, who was named executive chairman, said the board believes Joyner is well-suited to tackle CVS’s current challenges​.

Lynch’s tenure began during the pandemic when CVS’s revenue surged due to COVID-19 vaccinations.

She led efforts to push the company further into health care delivery services, including CVS’s $8 billion acquisition of home health care provider Signify Health and a $10.6 billion deal to acquire Oak Street Health, a Medicare-focused clinic network​.

Despite these moves, CVS’s financial struggles persisted, with rising costs in the Aetna insurance division and declining foot traffic in its retail stores fueling investor concerns.

CVS stock has fallen steadily, down about 10 percent since Lynch became CEO​​.

As Joyner steps into the CEO role, his priority will be stabilizing CVS’s financial performance and addressing the rising costs in its insurance and retail sectors.

CVS’s third quarter earnings report, expected on Nov. 6, will offer more insight into the company’s future direction as it navigates a changing health care landscape.

With hedge funds and analysts watching closely, Joyner will need to address the issues that have contributed to CVS’s repeated earnings cuts and rising medical costs.

With Lynch’s departure, the number of female CEOs in the S&P 500 drops to 45, representing just 9 percent of all top executives, according to data firm Equilar​​.

This article includes reporting from The Associated Press